Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-(2-Naphthyl)-Alanine is a synthetic, non-proteinogenic amino acid derivative characterized by the presence of a naphthalene ring attached to the β-carbon of alanine. It exists in both L and D enantiomeric forms. The compound is primarily used as a building block in peptide synthesis, where its bulky aromatic side chain can modulate peptide structure and function. In research settings, it has been studied for its ability to inhibit peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1), as well as prothrombin, suggesting potential utility in modulating protein folding and coagulation pathways[1][8]. Its hydrophobicity and steric properties make it valuable for designing peptides with enhanced stability or altered biological activity. Beta-(2-Naphthyl)-Alanine has also been explored as a fluorescent probe in receptor studies due to its aromatic moiety[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-(2-naphthyl)-alanine.